Phase 3 results posted, week of October 5, 2026: 12 industry trials
Industry sponsors posted results for 12 Phase 3 trials on ClinicalTrials.gov in the week of October 5 to 11, 2026. Together the trials enrolled 5,329 participants; the largest, Sanofi's AERIFY-2 trial, enrolled 1,234.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
The trials
- Sanofi posts results of Phase 3 Itepekimab trial in COPD. Sponsor: Sanofi. Condition: Chronic Obstructive Pulmonary Disease. Intervention: Itepekimab SAR440340. Phase: Phase 3. Enrollment: 1,234 (actual). Results first posted October 9, 2026. Record: NCT04751487 (AERIFY-2).
- Janssen posts results of Phase 3 aticaprant study in major depressive disorder. Sponsor: Janssen Research & Development, LLC. Condition: Depressive Disorder, Major. Intervention: Aticaprant. Phase: Phase 3. Enrollment: 871 (actual). Results first posted October 6, 2026. Record: NCT05518149 (VENTURA-LT).
- Sanofi posts results of Phase 3 MenACYW conjugate vaccine study in infants and toddlers. Sponsor: Sanofi Pasteur, a Sanofi Company. Conditions: Meningococcal Immunisation, Healthy Volunteers. Intervention: MenACYW conjugate vaccine. Phase: Phase 3. Enrollment: 840 (actual). Results first posted October 7, 2026. Record: NCT06284915.
- Intra-Cellular Therapies, Inc. posts results of Lumateperone schizophrenia relapse study. Sponsor: Intra-Cellular Therapies, Inc. Condition: Schizophrenia. Intervention: Lumateperone 42 mg. Phase: Phase 3. Enrollment: 592 (actual). Results first posted October 5, 2026. Record: NCT04959032.
- GlaxoSmithKline posts results of Phase 3 salbutamol safety study. Sponsor: GlaxoSmithKline. Condition: Asthma. Interventions: Salbutamol HFA-134a, Salbutamol HFA-152a. Phase: Phase 3. Enrollment: 471 (actual). Results first posted October 6, 2026. Record: NCT06261957.
- Hoffmann-La Roche posts results of Phase 3 IMpower030 atezolizumab trial in resectable NSCLC. Sponsor: Hoffmann-La Roche. Condition: Non-Small-Cell Lung. Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Nab-paclitaxel, Pemetrexed, Carboplatin, Cisplatin, Gemcitabine. Phase: Phase 3. Enrollment: 453 (actual). Results first posted October 9, 2026. Record: NCT03456063.
- DBV Technologies posts results of Phase 3 Viaskin Peanut study. Sponsor: DBV Technologies. Condition: Peanut Allergy. Intervention: Viaskin Peanut 250 µg. Phase: Phase 3. Enrollment: 393 (actual). Results first posted October 8, 2026. Record: NCT02916446 (REALISE).
- PTC Therapeutics posts results of Phase 3 ataluren safety study in Duchenne muscular dystrophy. Sponsor: PTC Therapeutics. Condition: Duchenne Muscular Dystrophy. Intervention: Ataluren. Phase: Phase 3. Enrollment: 265 (actual). Results first posted October 8, 2026. Record: NCT01247207.
- Vascular Therapies posts results of Phase 3 ACCESS 2 trial of Sirogen in ESRD patients. Sponsor: Vascular Therapies, Inc. Conditions: Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula. Intervention: Sirolimus. Phase: Phase 3. Enrollment: 136 (actual). Results first posted October 6, 2026. Record: NCT05425056 (ACCESS2).
- Hoffmann-La Roche posts results of Phase 3 alectinib rollover study. Sponsor: Hoffmann-La Roche. Condition: Neoplasms. Interventions: Alectinib, Crizotinib. Phase: Phase 3. Enrollment: 50 (actual). Results first posted October 9, 2026. Record: NCT03194893.
- Incyte posts results of Phase 3 axatilimab trial in chronic graft-versus-host disease. Sponsor: Incyte Biosciences Japan GK. Condition: Chronic Graft-versus-host-disease. Intervention: INCA034176. Phase: Phase 3. Enrollment: 21 (actual). Results first posted October 5, 2026. Record: NCT06263478.
- Instituto Grifols posts results of Phase II/III trial of plasma-derived AT-III concentrate. Sponsor: Instituto Grifols, S.A. Condition: Antithrombin III Deficiency. Intervention: Plasma-derived AT-III concentrate. Phase: Phase 2/Phase 3. Enrollment: 3 (actual). Results first posted October 7, 2026. Record: NCT00319228.
By the numbers
- Trials: 12, from 11 lead sponsors.
- Participants: 5,329 in all across 12 trials; median 423 per trial.
- Largest: Sanofi's AERIFY-2 trial, 1,234. Smallest: Instituto Grifols' NCT00319228 trial, 3.
- Sponsors with more than one trial: Hoffmann-La Roche (2).
- Phases as registered: 11 Phase 3, 1 Phase 2/Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.